Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12465 | 840 | 41.3 | 85% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 40 | 31853 | AIDS RESEARCH AND HUMAN RETROVIRUSES//HIV 1//AIDS |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | HGP 30 | Author keyword | 6 | 100% | 0% | 4 |
| 2 | VACCINE DEV BRANCH | Address | 3 | 100% | 0% | 3 |
| 3 | HIV 1 IMMUNOGEN | Author keyword | 3 | 50% | 0% | 4 |
| 4 | GP 160 | Author keyword | 2 | 67% | 0% | 2 |
| 5 | INTRASTRUCTURAL HELP | Author keyword | 2 | 67% | 0% | 2 |
| 6 | MOLECULAR CONTEXT | Author keyword | 2 | 67% | 0% | 2 |
| 7 | CD8 CELL ANTIVIRAL ACTIVITY | Author keyword | 1 | 100% | 0% | 2 |
| 8 | CD8 CELL NONCYTOTOXIC ANTIVIRAL RESPONSE | Author keyword | 1 | 100% | 0% | 2 |
| 9 | CNAR | Author keyword | 1 | 100% | 0% | 2 |
| 10 | HIV 1 GAG PEPTIDES | Author keyword | 1 | 100% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | HGP 30 | 6 | 100% | 0% | 4 | Search HGP+30 | Search HGP+30 |
| 2 | HIV 1 IMMUNOGEN | 3 | 50% | 0% | 4 | Search HIV+1+IMMUNOGEN | Search HIV+1+IMMUNOGEN |
| 3 | GP 160 | 2 | 67% | 0% | 2 | Search GP+160 | Search GP+160 |
| 4 | INTRASTRUCTURAL HELP | 2 | 67% | 0% | 2 | Search INTRASTRUCTURAL+HELP | Search INTRASTRUCTURAL+HELP |
| 5 | MOLECULAR CONTEXT | 2 | 67% | 0% | 2 | Search MOLECULAR+CONTEXT | Search MOLECULAR+CONTEXT |
| 6 | CD8 CELL ANTIVIRAL ACTIVITY | 1 | 100% | 0% | 2 | Search CD8+CELL+ANTIVIRAL+ACTIVITY | Search CD8+CELL+ANTIVIRAL+ACTIVITY |
| 7 | CD8 CELL NONCYTOTOXIC ANTIVIRAL RESPONSE | 1 | 100% | 0% | 2 | Search CD8+CELL+NONCYTOTOXIC+ANTIVIRAL+RESPONSE | Search CD8+CELL+NONCYTOTOXIC+ANTIVIRAL+RESPONSE |
| 8 | CNAR | 1 | 100% | 0% | 2 | Search CNAR | Search CNAR |
| 9 | HIV 1 GAG PEPTIDES | 1 | 100% | 0% | 2 | Search HIV+1+GAG+PEPTIDES | Search HIV+1+GAG+PEPTIDES |
| 10 | HUMAN T HELPER CELLS | 1 | 50% | 0% | 2 | Search HUMAN+T+HELPER+CELLS | Search HUMAN+T+HELPER+CELLS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SEROPOSITIVE INDIVIDUALS | 37 | 29% | 13% | 108 |
| 2 | RECOMBINANT GP160 | 18 | 40% | 4% | 36 |
| 3 | CYTO TOXIC RESPONSES | 16 | 47% | 3% | 25 |
| 4 | GP160 SUBUNIT VACCINE | 10 | 61% | 1% | 11 |
| 5 | LYMPHOCYTE PROLIFERATIVE RESPONSES | 8 | 39% | 2% | 15 |
| 6 | SERONEGATIVE PLASMA | 7 | 67% | 1% | 6 |
| 7 | GP160 | 5 | 18% | 3% | 24 |
| 8 | CHEMOKINES RANTES | 5 | 55% | 1% | 6 |
| 9 | INFECTED CD4 CELLS | 4 | 75% | 0% | 3 |
| 10 | RECOMBINANT GP160 VACCINE | 4 | 75% | 0% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Control of HIV-1 infection by soluble factors of the immune response | 2004 | 56 | 162 | 22% |
| Antibody-dependent cellular cytotoxicity in HIV infections | 1996 | 69 | 48 | 50% |
| Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections | 1999 | 58 | 155 | 23% |
| Therapeutic AIDS vaccines | 2006 | 15 | 140 | 36% |
| A soluble factor(s) secreted from CD8(+) T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation | 2002 | 36 | 97 | 26% |
| CYTOTOXIC LYMPHOCYTES-T AGAINST HIV | 1990 | 197 | 56 | 43% |
| Role of cellular immunity in protection against HIV infection | 1997 | 86 | 336 | 20% |
| Cd8(+) T cell mediated noncytolytic inhibition of human immunodeficiency virus type I | 2001 | 12 | 164 | 46% |
| Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection | 2004 | 15 | 131 | 33% |
| CYTOTOXIC T-CELL RECOGNITION OF HIV PROTEINS AND PEPTIDES | 1991 | 138 | 66 | 42% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | VACCINE DEV BRANCH | 3 | 100% | 0.4% | 3 |
| 2 | REMUNE TRIAL | 1 | 100% | 0.2% | 2 |
| 3 | UNIT VIRAL IMMUNOL | 1 | 50% | 0.2% | 2 |
| 4 | OCCUPAT ENVIRONM MED ASSOC THAILAND | 1 | 40% | 0.2% | 2 |
| 5 | BC EXCELLENCE | 1 | 50% | 0.1% | 1 |
| 6 | CIENI | 1 | 50% | 0.1% | 1 |
| 7 | CLIN TRIALS UNIV | 1 | 50% | 0.1% | 1 |
| 8 | FORMULAC ENVASE | 1 | 50% | 0.1% | 1 |
| 9 | JOINT DIS RHEUMAT | 1 | 50% | 0.1% | 1 |
| 10 | MED GENITOURINARY MED COMMUNICABLE DIS | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000189685 | SIV//SHIV//SIMIAN IMMUNODEFICIENCY VIRUS |
| 2 | 0.0000185836 | PARTNERS AIDS//HIV PATHOGENESIS PROGRAMME//DORIS DUKE MED |
| 3 | 0.0000179440 | HIV 1 GP41//GP120 CD4 INTERACTION//CD4 RECEPTOR |
| 4 | 0.0000125932 | SERV REG MALAD INFECT//EQUIPE INTERFERON CYTOKINES//PHARMA NEW TECHNOL |
| 5 | 0.0000113035 | EXPOSED UNINFECTED//HESN//IMMUNOBIOL HIV UNIT |
| 6 | 0.0000104292 | IAVI NEUTRALIZING ANTIBODY//DUKE HUMAN VACCINE//HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER |
| 7 | 0.0000093731 | ELECTRON ION INTERACTION POTENTIAL//INFORMATIONAL SPECTRUM METHOD//DECEPTIVE IMPRINTING |
| 8 | 0.0000091098 | IMMUNE RECONSTITUTION//CLIN MOL RETROVIROL SECT//IMMUNE ACTIVATION |
| 9 | 0.0000084704 | PEPTIDE PROT CHEM//PHYSICOCHEM UNIT//QUIM PEPTIDS PROT |
| 10 | 0.0000084006 | DOUBLE POSITIVE T CELLS//CD4CD8 T CELLS//CD8 INFECTION |